Showing results (91-100 of 139) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
The New England Journal of Medicine|September 4, 2009
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449Charles M Rudin, Christine L Hann, John Laterra, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.
RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsPatricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Neuro-Oncology Advances|January 28, 2021
Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trialGary L Gallia, Matthias Holdhoff, Henry Brem, et al.
JAMA Oncology|October 29, 2020
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung CancerBairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, et al.
Molecular Cancer Therapeutics|June 10, 2024
TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to RadiotherapyTriet Nguyen, Francesca A Carrieri, Nick Connis, et al.
Frontiers in Oncology|August 22, 2022
Sex-specific differences in immunogenomic features of response to immune checkpoint blockadeSusan C Scott, Xiaoshan M Shao, Noushin Niknafs, et al.
Molecular Cancer Therapeutics|April 26, 2024
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapyTriet Nguyen, Francesca Anna Carrieri, Nick Connis, et al.
Pageof 14